Y-mabs closes deals in China and Europe for the firm's two drugs against pediatric cancer
According to these new deals, Y-mabs will pass on responsibility for the distribution of its drugs danyelza and omburtamab in China and Europe – the task will instead be passed onto various partners.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
The Danish but US-listed biotech firm Y-mabs has entered two new partnerships in China and Eastern Europe, respectively.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
